Angiodynamics INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
AngioDynamics reported a net loss of $8.1 million on $78.4 million in revenue for the third quarter of fiscal year 2026, driven by strong Med Tech segment growth.
NASDAQ
AngioDynamics reports increased Q2 2026 net sales and improved gross margin, significantly reducing its net loss compared to the prior year.
NASDAQ
AngioDynamics reports a 12.2% increase in net sales to $75.7 million and a reduced net loss of $10.9 million for the first quarter of fiscal year 2026, driven by strong Med Tech performance.
NASDAQ
AngioDynamics' Q3 2025 results show a decrease in overall revenue due to divestitures, but growth in the Med Tech segment partially offset the decline.
NASDAQ
AngioDynamics' Q2 2025 results show a decrease in revenue due to divestitures, but an increase in gross profit margin and a reduction in net loss.
NASDAQ
10-Q: AngioDynamics Reports Net Loss in First Quarter of Fiscal Year 2025 Amidst Strategic Divestitures
AngioDynamics experienced a net loss in the first quarter of fiscal year 2025, primarily due to strategic divestitures and product line discontinuations, despite growth in its Med Tech segment.
NASDAQ
AngioDynamics experienced a substantial net loss in the third quarter of fiscal year 2024, driven by a goodwill impairment charge and restructuring costs, despite growth in its Med Tech segment.